Clinical Trials Logo

Clinical Trial Summary

In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.

Clinical Trial Description

Rationale: Glioblastoma (GBM), the most common primary brain tumor, is without exception lethal. Every year 1000 patients are diagnosed with this disease in the Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumors inevitably recur. Currently, there is no gold standard at time of recurrence and treatment options are limited. In a retrospective study in two Dutch neuro-oncology centers, the overall survival (OS) for patients with recurrent GBM receiving best supportive care was 3 months, while patients receiving systemic treatment (usually nitrosurea), radiation therapy or surgery followed by systemic treatment or radiotherapy had respectively 7.3 months, 9.2 months and 11 months OS. Unfortunately, the results of dedicated trials with new drugs have been very disappointing. For those to be meaningful, extensive molecular screening is needed. The goal of the project is to obtain the evidence for changing standard of care procedures to include extensive molecular diagnostics and consequently adapt care guidelines for this specific patient group with very poor prognosis by offering optimal and timely benefit from novel therapies, even in the absence of traditional registration trials for this small volume cancer indication. Objective: To determine the value of and generate the clinical evidence for routine application of Whole Genome Sequencing (WGS)-based diagnostics and targeted therapy guidance for glioblastoma patients at time of first recurrence. Study design: Prospective diagnostic multicenter cohort study Study population: Adult glioblastoma patients with recurrent disease that are undergoing resection or debulking as part of their standard care and from whom written informed consent is obtained. Intervention: A 10 mL blood sample will be drawn once to assess each patient's germline DNA background variation that will discriminate somatic mutations from the patient's germline DNA background variations. All other interventional procedures required to perform this study are part of standard procedures. Main study parameters/endpoints: Primary study endpoint: Overall survival Secondary study endpoints: - Tumor and blood collection success rate (target >85% of all patients included) - Number of successful WGS reports (reports for >80% of patients for which tumor material was collected) - Number of targeted treatment options identified (at least one potentially actionable DNA alteration in >75% of patients with a WGS report) - Number of experimental treatments available for GBM patients (relevant (off-label) drugs for at least 50% of the identified indications should be available through a study, including the Drug Rediscovery Protocol (DRUP) - Thirty-two percent of patients starting a targeted treatment in presence of actionable variant (currently 16%) ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05186064
Study type Interventional
Source UMC Utrecht
Contact Mark Y van Opijnen
Phone 0031-88-9797900
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date April 1, 2022
Completion date April 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Not yet recruiting NCT04910022 - Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma Phase 1/Phase 2
Suspended NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Active, not recruiting NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Completed NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2
Recruiting NCT01985087 - A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 Phase 1/Phase 2
Withdrawn NCT01622764 - 89Zr-RO5323441 PET Imaging in Glioblastoma Phase 2